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Objective: This study compared postoperative patient comfort and the surgical outcome of endovenous laser ablation
(EVLA) or stripping of the great saphenous vein, both performed in conjunction with high ligation.
Methods: The study randomized 100 patients with primary trunk varicosities of the great saphenous vein (CEAP clinical
class II to IV) to EVLA or stripping. The success of surgery was followed-up by duplex ultrasound imaging at 1, 4, and
16 weeks. Primary end points were the size of the hematoma 1 week after the operation and the preoperative
disease-specific Chronic Venous Insufficiency Questionnaire (CIVIQ) quality of life score compared with 4 weeks
postoperatively. Secondary end points were postoperative symptoms (pain, use of analgesics, paresthesia at the ankle,
residual hematoma), complications, time taken to resume work, the patient’s satisfaction with the cosmetic outcome, and
the CIVIQ quality of life score at 16 weeks.
Results: The groups were well matched at baseline. In all, 95 patients could be followed up in accordance with the
protocol. The treatment was successful in all patients. Endovenous laser ablation was associated with an occlusion rate of
100%. Hematomas were significantly smaller after EVLA (median [quartiles]) at 125 (55-180) cm2 vs stripping 200
(123-269) cm2 (P  .001). No difference was registered between groups for the CIVIQ quality of life score, with EVLA
at1.25 (7.5-11.25) vs stripping at 4.38 (5.94-14.38; P .34). Several postoperative symptoms favored EVLA, but
the only significant differences were seen in the minor side effects of surgery at 1 and 4 weeks and discomfort due to
paresthesia at the ankle in the first postoperative week. EVLA was associated with a longer period of time until return to
work (median [quartiles]) of 20 (14-25.5) days vs 14 (12.8-25) days (P  .054).
Conclusion: Endovenous laser ablation combined with high ligation is safe and effective. Postoperative hematomas are
significantly smaller than those after stripping. Short-term quality of life is at least as good as that after stripping. The
long-term results warrant further investigation. (J Vasc Surg 2008;47:822-9.)Stripping of the great saphenous vein (GSV) com-
bined with high ligation is the standard procedure for the
treatment of GSV incompetence.1 In recent years, new
and less invasive methods have been developed to con-
trol the insufficient truncal vein, such as endovenous
laser ablation (EVLA), radiofrequency ablation, foam
sclerotherapy, or cryostripping. Of these, EVLA is the
most commonly used procedure and has been rapidly
accepted by venous surgeons in several areas of the
world. Some clinicians offer this procedure as the treat-
ment of choice to patients with venous reflux.2 One
major advantage of EVLA is the possibility to treat GSV
reflux without a groin incision or a dissection at the
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822saphenofemoral junction (SFJ), which has made it suit-
able for use in medical offices.3
We introduced EVLA rather tentatively at St
Franziskus Hospital in 2002 and continued to dissect the
SFJ, because correct SFJ dissection was deemed manda-
tory before the introduction of endovenous treatment to
avoid high rates of groin recurrence.4 Long-term data
about groin recurrence after minimally invasive GSV
treatment without SFJ dissection are not yet available.
The replacement of any standard treatment should be
supported by randomized controlled trials that demon-
strate the parity or superiority of the new treatment. We
present the results of a randomized controlled trial compar-
ing our use of EVLA and stripping of the GSV. The aim of
this study was to investigate whether EVLA enhances the
patients’ postoperative comfort, yields better results, and is
associated with lower complication rates than stripping,
which is currently the standard surgical procedure for var-
icose veins.
METHODS
Patients. At their first visit to the outpatient unit,
patients with varicose veins underwent duplex ultrasound
(DUS) scanning after history taking and physical examina-
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appropriate surgical treatment. All suitable patients were
asked to participate in the study. Inclusion criteria were the
following:
● Primary GSV reflux, complete or partial, as shown by
DUS imaging. The latter investigation was performed
with the patient standing. Reflux for0.5 seconds and
with extension beyond the upper 10 cm of the GSV at
the Valsalva maneuver was deemed significant.
● C-class of CEAP II to IV; that is, varicose veins,
swelling, and hyperpigmentation or dermatitis of the
leg.
● Predicted availability of the patient for the follow-up
investigations.
Exclusion criteria were the following:
● age 18 or 65 years at randomization;
● pregnancy or breast-feeding;
● mental incapacitation or patients represented by an
attorney,
● CEAP clinical classification I, V, and VI;
● further planned surgery apart from stripping/EVLA,
high ligation and stab avulsion, such as perforator
dissection or TriVex shaving (Smith & Nephew, Inc,
Andover, Mass);
● GSV diameter of 2 cm;
● routine use of aspirin or nonsteroidal anti-inflammatory
drugs was discussed to inhibit obliteration of the vein
after laser treatment in the early days of EVLA;
● contraindication for the use of stripping or EVLA;
● reflux of the small saphenous vein;
● deep venous reflux; or
● simultaneous participation in another clinical trial.
The study recruited 100 patients who fulfilled the
inclusion criteria from September 2004 to March 2006;
90% of these had symptomatic varicose veins. The conduct
of the study included standard surgical procedures, imple-
mentation of quality control measures (monitoring), local
statutory board approval before the start of the intervention
phase, and written informed consent from all patients.
Randomization. Immediately before surgery, the pa-
tients were randomized to receive stripping or EVLA of the
GSV. Patients were informed about their group allocation
after the operation.
Preoperative assessments. One day before surgery, a
physician performed a physical examination and recorded
the patients’ signs and symptoms. The C class of CEAP was
defined and a DUS scan was obtained to determine the
diameter of the GSV and the extent of venous insufficiency.
Patients completed the Chronic Venous Insufficiency
Questionnaire (CIVIQ) quality of life (QOL) question-
naire and rated the pain originating from leg veins on a
10-cm visual analog scale (VAS)5 the evening before the
operation. The venous clinical severity score (VCSS)6 was
determined to ensure comparability of groups.
The operations were performed by experienced vein
surgeons who conduct50 vein operations per year. A fewoperations (20%) were performed by surgeons in training
under the supervision of a consultant surgeon as part of the
teaching program at the unit. All visible varicose veins were
marked before the operation with the patient in standing
position.
Stripping. After dissection of the SFJ, ligature of all
side tributaries, and high ligation of the GSV, a standard
olive-tip stripper was inserted into the GSV. Access to the
GSV was achieved through a small incision either at the
ankle or just below the knee. The next step was stab
avulsion of all marked varicose branches. The small stabs
(about 2 mm) were left open. Stripping of the GSV was
followed by closure of the skin at the groin and ankle or
below the knee.
Endovenous laser ablation. The first step was also
high ligature of the GSV in conjunction with ligature of all
side tributaries in the groin. This was followed by EVLA of
the GSV, either by inserting the laser fiber into the GSV
from the groin down to the point of distal insufficiency or
by puncturing the GSV at the ankle. Laser energy was
applied when the fiber was retracted in 3- to 5-mm steps.
The targeted energy dose was 20 to 30 J/cm of treated
vein. Single impulses were applied for 1 second after each
step of retraction of the fiber. The power of the 810-nm
diode laser (Diomed Inc, Andover, Mass) was set to 10 to
12 W at the thigh, reduced to about 6 W at the level of the
knee where the vein tends to lie rather superficially in
the subcutaneous tissue, and 4 to 6 W at the lower leg. The
EVLA procedure was done without the use of tumescence.
Finally, varicose side tributaries were removed by stab
avulsion.
Postoperative care. In both groups, an elastic above
knee stocking was applied on the leg after the operation.
The wound dressing was changed 2 days after the opera-
tion. An elastic class II compression stocking had to be
worn for 2 weeks, day and night, and for a further 6 weeks
during the day in the group that had undergone stripping.
The EVLA patients wore the compression stocking during
the day until all visible hematomas had resolved. On the day
of surgery and the first postoperative day, 20 to 40 mg of
enoxaparin was administered as thrombosis prophylaxis.
Postoperative assessments. Postoperative investiga-
tions were scheduled for 2 days, and at 1, 4, and 16
weeks. Every evening during the first 4 weeks, the pa-
tients used the VAS to rate their pain level in the oper-
ated on leg and recorded their use of analgesics in study
diaries. At every follow-up visit, a surgeon performed a
clinical investigation to assess the outcome and compli-
cations of surgery. Patients were asked about the occur-
rence of adverse effects of the operation and particularly
about paresthesia in the medial lower leg and the medial
ankle, which is known to be a rather common side effect
after stripping and EVLA of the GSV.7,8 Patients with
paresthesias rated their subjective disturbance on a scale
from 1 (very low) to 5 (very high).
To estimate the success of occlusion or removal of the
insufficient GS, DUS scans were made at 1, 4, and 16 weeks
after the operation. One week after surgery, the size of the
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covering the hematomas with a transparent foil and mea-
suring the covered stained areas. In the present study, the
term hematoma is used as a synonym for all aspects of
subcutaneous bleeding such as solid hematoma or bruising.
This procedure was performed at the outpatient unit by
nurses who were not informed of the patient’s treatment
group.
Patients completed the CIVIQQOL questionnaire at 4
and 16 weeks postoperatively and were asked to rate their
degree of satisfaction with the cosmetic outcome on a scale
from 1 (very good) to 5 (very poor). At 16 weeks, the
patients were also asked whether they would opt for the
same treatment again. The period of absence from work
was recorded for those who were employed.
Study end points. Primary end points were the size of
the hematoma 1 week after surgery in the medial half of the
leg and the CIVIQ QOL score before surgery to 4 weeks
after surgery. The CIVIQ score is a disease-specific QOL
score for patients with chronic venous disease.9 It has been
used in a randomized controlled trial comparing stripping
and radiofrequency ablation of the GSV.10 The score is
calculated from a 20-question questionnaire. The response
to each question about activities of daily living and well-
being is rated on a scale of 1 (minimum negative effect) to
5 (maximum negative effect). The questions are assigned to
one of four dimensions: pain, physical, social, and psycho-
logic; thus, four subscores constitute the overall score. At
calculation, the scores are transferred to a scale from 0 to
100, where 100 represents the best possible QOL and 0 the
least.
Statistics. Analyses of all patients who underwent the
operation (intent-to-treat analysis) and of patients without
any major deviation from the study protocol (per-protocol
analysis) were performed. Pilot data from clinical routine
(hematoma size of 20 patients, 10 with stripping and 10
with EVLA) and data from the CIVIQ score of the En-
dovenous Radiofrequency Obliteration (Closure) Versus
Ligation and Vein Stripping (EVOLVeS) Study were used
for estimation of the sample size.
Sample size estimations were performed as follows
(one-tailed type I error, 1.236%; type II error, 10%):
CIVIQ score before surgery to 4 weeks after surgery—
difference of means, 8; pooled standard deviation, 10.95;
and hematoma 1 week after surgery—difference of means,
16.3 cm2; pooled standard deviation, 18.22 cm2.
The calculations resulted in a sample size of 50
patients per group for the primary end point of CIVIQ
score before surgery to 4 weeks after surgery and 35
patients per group for the other primary end point of
hematoma 1 week after surgery. By the chosen sample
size of 50 patients per group, the type II error for
hematoma 1 week after surgery was reduced to 2%.
Because the data of the primary end points were not
normally distributed (test of normality: Kolmogorov-
Smirnov with the Lilliefors significance correction; type I
error, 5%), nonparametric Mann-Whitney U tests were
used for analysis. The performance of an interim analysis(O’Brian-Fleming) and the definition of two primary end
points (Bonferroni corrections) required adjustments for P
values; thus, only values of P  .01236 were deemed
significant (one-tailed type I error, 2.5%).
For group comparisons of all other metric variables, the
Mann-Whitney U test was used. Categoric variables were
compared by the 2 or the Fisher exact test. All tests were
two-tailed with a type I error of 5% (P  .05). Besides
the above-mentioned adjustments, no further adjustments
for P values, such as Bonferroni corrections, were made. As
a consequence, significances at P  .05 for comparisons of
all variables except the primary end points reflect the prob-
ability of differences that may at best be used for generating
hypotheses but do not prove them. Unless otherwise men-
tioned, descriptive data in the text refer to medians, with
quartiles in parenthesis.
RESULTS
From September 2004 to April 2006, 50 patients were
randomized to each group, representing 15.6% of all 642
patients treated for varicose veins during the study period.
One patient in the EVLA group was excluded from the
analysis because the guidewire for the laser fiber could not
be passed through the GSV intraoperatively and the patient
eventually had to undergo stripping. This patient’s postop-
erative course was uneventful and a good surgical outcome
was achieved.
Two patients in the stripping group and two in the
EVLA group were excluded from the per-protocol analysis
because at least one primary end point could not be as-
sessed. Three patients missed the 4-week postoperative visit
(CIVIQ documentation), and the size of the hematoma in
one patient was not recorded. In the intention-to-treat
analysis, the missing values for the hematoma size and the
CIVIQ score 4 weeks postoperatively were replaced by the
poorest of all recorded values.
The per-protocol analysis included 48 patients in the
stripping group and 47 in the EVLA group. Only the
results of the per-protocol analysis are presented; however,
the results of the intent-to-treat analysis do not differ
significantly from these.
Demographic and preoperative clinical findings were
well matched between the groups. The details are listed in
Table I. Data for the surgical procedures are summarized in
Table II. Notably, the same number of stab incisions was
performed in both groups. This shows that varicose lateral
branches were equally distributed and stab avulsions had no
biasing influence on the size of the hematoma.
The results of the primary end points, namely, hema-
toma size and the course ofQOLdetermined by the change
in the CIVIQ global index score from preoperative to 4
weeks postoperatively, are shown in the Fig. Data for
postoperative pain and the use of analgesics are in Table III,
and all other data pertaining to the secondary end points are
in Table IV.
For the primary end point of hematoma size, the statis-
tical test revealed a highly significant difference between
aser ab
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cm2) and stripping at 200 cm2 (123-269 cm2; P  .001).
Also supporting this fact is that at 4 weeks postoperatively,
significantly fewer patients in the EVLA group had residual
hematomas. The other primary end point—change in the
CIVIQ global score—did not show any significant differ-
ence, with the EVLA group at1.3 (7.5 to 11.3) and the
stripping group at 4.4 (5.9 to 14.4; P  .342).
The CIVIQ global index scores as well as the four
subscores for the pain, physical, social, and psychologic
dimensions were compared at baseline and at 4 and 16
weeks postoperatively between the groups. Finally, the
Table I. Demographic data and preoperative clinical findi
Variable
EVLA (n  47)
Median (quartiles) or %
Age, y 46 (38-57)
Sex
Male 21
Female 79
BMI 26.6 (23.7-30.4)
CEAP classification
2 74
3 19
4 7
Extension of reflux
Thigh 21
Knee 43
Ankle 36
GSV diameter, cm 0.80 (0.7-1.0)
Pain, pre-op,a cm 0.4
Swelling of the legs 51.1
Heaviness in the legs 61.7
Cramps 38.3
Other symptoms 4.3
CIVIQ, preoperative 84
VCSS, preoperative 4.24
CIVIQ, Chronic Venous Insufficiency Questionnaire; EVLA, endovenous l
aMeasured by 10-cm visual analog scale.
Table II. Procedural details
Variable
EVLA Stripping
P
Median
(quartiles)
or %
Median
(quartiles)
or %
Operative time, min 67 (58-78) 60 (51-78) .302
Treated GSV, length cm 60 (54-70) 71 (43-75) .517
Stab incisions, No. 25 (20-35) 25 (16-32) .768
Surgeon distribution .778
1 19.1 12.5
2 2.1 2.1
3 25.5 18.8
4 40.4 45.8
5 12.8 20.9
Anesthesia .208
General 48.9 34
Regional 51.1 66
EVLA, Endovenous laser ablation; GSV, great saphenous vein.changes in scores from preoperative to 16 weeks postoper-atively and from 4 to 16 weeks postoperatively were com-
pared. At the follow-up visits, the global score and the
subscores did not reveal noteworthy differences. Most of
the measures of secondary end points indicated a tendency
in favor of EVLA; however, only a few were superior on
statistical testing. The EVLA group took a longer time to
resume work; the difference was notable.
Intraoperatively and during follow-up, neither group
experienced major surgical complications, repeat surgery,
deep vein thrombosis, or skin necrosis. One patient in the
EVLA group was rehospitalized 2 weeks postoperatively
owing to pain and signs of skin inflammation on the thigh
over the treated GSV. The signs and symptoms resolved
after treatment with systemic and local anti-inflammatory
drugs for 4 days, and the patient’s subsequent postopera-
tive course was uneventful. This patient’s surgical report
revealed that the dose of laser energy applied was higher
than that routinely used (40 J/cm), causing transient ther-
mal damage to the skin.
Residual hematomas were present in 12% of the EVLA
group and in 10% of the stripping group after 16 weeks.
Most of these hematomas were in recession, but mild
hyperpigmentation was noted in some patients.
In terms of the overall outcome, very good results were
achieved in both groups. Quality of life was increased at 16
weeks postoperatively, and the success rate of the surgery
was 100%. No major adverse event occurred during the
study period. At 16 weeks, 91% in the EVLA group and
81% in the stripping group were content or very content
with the cosmetic outcome, and 96% of EVLA patients and
89% of stripping patients would opt for the same treatment
Stripping (n  48)
PMedian (quartiles) or %
46.5 (39-53) .710
.480
29
71
25.3 (23.5-27.7) .237
.625
69
27
4
.482
21
52
27
0.80 (0.7-1.1) .764
0.8 .03
58.3 .539
75.0 .190
22.9 .123
6.3 .999
77 .219
4.82 .195
lation; GSV, great saphenous vein; VCSS, venous clinical severity score.ngsagain.
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Endovenous laser ablation has been established as a less
invasive alternative treatment to saphenous vein stripping
and has become popular among vein surgeons. A number
of case series and nonrandomized trials comprising more
than 1000 patients have been published, demonstrating the
safety and efficacy of this treatment. Mid-term results after
a median follow-up of 3 years are available and show
acceptable recurrence and recanalization rates of 0% to
11%.11-17
Rasmussen et al18 recently performed a prospective ran-
domized trial to compare EVLA without high ligation and
stripping with high ligation. Additional mini-phlebectomies
for varicosities were performed in both groups. The sample
size was about 60 per group. All procedures were per-
formed in an office-based setting. The authors registered a
significant reduction in postoperative pain and bruising
after laser ablation. Efficacy and safety were identical, the
Fig. Box and whisker plots show results of the primary
quality of life determined by the change in the Chroni
score, from preoperative to 4 weeks postoperatively afte
Inc, Andover, Mass). The horizontal line inside the box i
the box ends represent values that are 25% are greater and
is largest observed value that is not an outlier, and the low
No outliers were detected.
Table III. Postoperative pain and use of analgesics
Variable EVLA Median (quar
VAS valuea
Day of surgery 4.40 (1.90-5.50)
Post-op day 1 2.80 (1.00-4.20)
Post-op day 2 1.80 (0.50-3.28)
Maximum value 4.40 (2.90-6.00)
Post-op day 7 2.13 (1.17-3.61)
Post-op day 28 0.51 (0.14-1.21)
Use of analgesics
Post-op week 1, mg/dayb 14.29 (7.14-35.71
Total days of use, No. 2.00 (1.00-5.00)
EVLA, Endovascular laser ablation.
a10-cm visual analog scale.
bTramadol.cost of surgery after stripping was lower, and the period ofabsence from work was brief in both groups (7.0 vs 7.6
days).18
In a further randomized controlled trial published in
2005 that compared EVLA with stripping, de Medeiros et
al19 reported a significant difference in the intensity of
swelling and the size of the bruise as well as the overall
benefit of surgery according to the patients’ estimation, all
in favor of EVLA. In this trial, 20 patients with varicosities
in both legs were treated with EVLA (also combined with
high ligation) in one leg and conventional stripping in the
other.
In the present randomized controlled trial comprising a
sample size of 50 patients per group, the two groups could
be compared in respect of the two treatment modalities for
GSV because all other aspects of surgery were identical.
Thus, the effect of EVLA on the patients’ postoperative
course could be studied very specifically. Our results show a
significantly smaller hematoma size and a slight advantage
points, (left) hematoma size and (right) the course of
ous Insufficiency Questionnaire (CIVIQ) global index
ping and endovascular laser treatment (EVLT, Diomed
edian value (50% of ratings have values within the box)
re less than the values within the box. The upper whisker
isker is the smallest observed value that is not an outlier.
Stripping Median (quartiles) P
5.20 (2.53-7.15) .087
3.45 (0.93-4.88) .542
2.30 (0.57-3.95) .374
5.30 (3.53-7.38) .239
2.52 (1.24-4.19) .556
0.55 (0.10-1.62) .884
17.86 (7.14-33.93) .451
2.00 (1.00-7.25) .447end
c Ven
r strip
s the m
25% a
er whtiles)
)for EVLA for a number of symptoms during the first weeks
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between the groups postoperatively. At 16 weeks after
surgery, there was no difference in the outcome of surgery
and the patients’ degree of comfort.
We performed stab avulsion of all visible varicose veins in
addition to the GSV treatment because our patients generally
expect comprehensive treatment of their venous disease
within a single hospital stay. The mini-phlebectomies may
have contributed significantly to morbidity in the postopera-
tive phase. The hematomas were partly due to avulsions,
particularly in the EVLA group. However, an equal num-
ber of stab incisions were performed in both groups, imply-
ing an equal contribution to the hematoma size in both
groups.
Of the secondary end points, the period of absence
from work was longer after EVLA. The reason for this
difference is not clearly discernible. Morbidity was by no
means increased in the EVLA group; rather, the opposite
was true. One reason may have been differences in social
background between the groups, but this factor was not
considered in the study protocol. Wright et al20 reported a
significant influence of the patients’ social class on the time
taken to resume work after varicose vein surgery, but reg-
istered no effect of the surgical procedure on this outcome.
In their analysis of 192 cases, the median time of absence
from work was 3 weeks.20 Because postoperative morbidity
was less severe in our EVLA group, we conclude that sick
leave is a poor indicator of clinical outcome.
Significant advancements have been made in EVLA in
the last few years. In contrast to our protocol, which
Table IV. Operative results
Variable
Successful GSV treatment post-op, %a
At 7 days
At 4 weeks
At 16 weeks
Residual hematomas, post-op %
At 4 weeks
At 16 weeks
Paresthesias after surgery
To day 2, %
Discomfort rating (1/2/3/4/5)b
To 1 week, , %
Discomfort rating (1/2/3/4/5)b
To 4 weeks, %
Discomfort rating (1/2/3/4/5)b
To 16 weeks, %
Discomfort rating (1/2/3/4/5)b
Compression stocking use, median (quartiles) days 4
Time to resume work, median (quartiles) days 2
Cosmetic result, patient rating score
At 4 weeks (1/2/3/4/5)c
At 16 weeks (1/2/3/4/5)c
Patients would have treatment again, %
EVLA, Endovenous laser ablation; GSV, great saphenous vein.
aDetermined by duplex ultrasound scan.
b1  no discomfort, 5  maximum discomfort.
c1  very good cosmetic result, 5  very poor cosmetic result.involved step-by-step retraction of the laser fiber, the slid-ing technique is currently given preference. This appears to
reduce the side effects of the treatment as well permit
application of a smaller dose of energy.21 Most practitio-
ners recommend the use of a tumescent solution to separate
the GSV from the skin and prevent thermal damage of
surrounding tissue.22 The tumescent solution also empties
the blood in the vein and approximates the laser fiber to the
vein wall, which is desirable when a laser with a longer
wavelength is used because the vein wall is the target tissue
in this setting. When an 810-nm laser is used, the blood in
the vein is the target tissue because laser light of this
wavelength is predominantly absorbed by hemoglobin.
The compression effect of the tumescent solution might be
unfavorable in this regard. This subject warrants further
investigation. The treatment protocols may differ for the
individual laser wavelengths in respect of the optimal en-
ergy dose or the use of tumescent solution.23-25
We registered a lower rate of paresthesia along the
saphenous nerve in the EVLA group. This was surprising
because our early experience showed paresthesia to be the
most common side effect of EVLA. Saphenous reflux down
to the ankle was present in 36% of the patients in the EVLA
group and in 27% in the stripping group. Nevertheless,
because some of our surgeons prefer to treat the entire
GSV, including the nonrefluxing part at the lower leg,
treatment of the GSV was extended to the lower leg in 50%
of patients in the EVLA group and in 60% of patients in the
stripping group. Finally, the median length of the treated
GSV was 60 cm and 70 cm, respectively. Limiting the
VLA Stripping P
95.7 97.9 .617
00 100 .999
00 100 .999
34.0 58.3 .024
12.8 10.6 .999
8.5 16.7 .355
/0/0/0 0/2/6/0/0 .009
19.1 31.3 .238
/1/0/0 1/5/3/2/1 .022
34.0 43.8 .402
/2/0/0 2/5/2/2/1 .348
48.9 47.9 .999
/2/0/0 1/2/0/1/0 .652
(28.0-88.0) 75.00 (58.0-105.0) .001
(14.0-25.5) 14.0 (12.8-25.0) .054
7/2/1/0 24/15/5/1/3 .278
6/4/0/0 26/12/6/2/1 .564
95.7 89.4 .435E
1
1
2/2
4/4
1/9
4/9
2.00
0.00
26/1
26/1extent of GSV ablation to the thigh or below knee level,
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minimize the problem of saphenous nerve damage.
Endovenous laser ablation is often performed without
surgical treatment of the SFJ. The laser fiber is placed near
the SFJ under DUS control, and the GSV is treated down-
ward until just below the knee. Nevertheless, omission of
the groin incision and dissection of the SFJ is a strongly
debated issue among venous surgeons who treat saphenous
reflux.26
On the one hand, the minimally invasive procedure
contributes to the patient’s comfort, reduces morbidity
secondary to the groin incision, and can be performed in a
doctor’s office. Not dissecting the SFJ may also be advan-
tageous because subsequent neovascularization from the
dissected groin is discussed as a major reason for groin
recurrence after stripping. Incomplete dissection of the SFJ
is known to be a reason for groin recurrence after strip-
ping.1 Besides, the common femoral vein may be injured
when the laser fiber is inserted too far.
The question of SFJ dissection was not primarily ad-
dressed in our trial because all patients underwent high
ligation. We achieved a 100% occlusion rate of GSV after
EVLA using rather low energy doses. No major or minor
complications secondary to the surgical intervention in the
groin were registered in either group, and primary wound
healing of the incision in the groin was achieved in all
patients.
However, the possibility of minimizing the operative
procedure appears to be the real advantage of endovenous
treatment. If 40 cm of incompetent GSV is treated without a
groin incision, a tumescent solution is used, and stab avulsions
are omitted, the trauma secondary to surgery is minimized;
therefore, this treatment is most suitable in an office-based
setting. Published results indicate short periods of absence
from work and minimal postoperative symptoms as well as a
high degree of comfort for the patient.3,11-18,27 A final state-
ment about the benefit of treating GSV without dissection
of the SFJ can be made only when the outcome of the
procedure after several years is known.
CONCLUSION
Postoperative patient comfort and the surgical out-
come of EVLA in the short term are not inferior to those
after stripping when combined with ligation of the saphe-
nofemoral confluence. Postoperative pain and QOL assess-
ment did not differ, although stripping resulted in larger
hematomas. Thus, the higher cost of disposable laser
equipment can hardly be justified by the rather minimal
benefits registered in the postoperative course. Better re-
sults in terms of the patients’ comfort may be achieved by
the use of EVLA without high ligation and stab avulsion.
The long-term results of this procedure warrant further
investigation.
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I commend the authors for providing a prospective, random-
ized comparison of endovenous laser ablation (EVL) of the great
saphenous vein with conventional surgical stripping in symptom-
atic patients. High ligation of the saphenofemoral confluence was,
unfortunately, also performed in conjunction with laser ablation,
which is generally not the current practice in the United States.
Primary end points revealed less size of bruising with EVL at 4
weeks postoperatively, but quality of life and pain scores showed no
difference. Secondary softer end points were not statistically differ-
ent in the two groups, although there was a tendency in favor of the
EVL. Despite these findings, the patients receiving laser ablation
had longer sick leave than the patients having stripping. Thus, GSV
laser ablation in this setting did not show anymajor advantage over
surgical stripping.
Obviously, there are differences in treatment aspects between
Austria and the United States. In the United States, the EVL
targeted energy dose is usually 20 to 30 J/cm, tumescence is
obligatory (even when general anesthesia is used), the duration of
wearing a compression stocking is shorter, and, rarely is low-molecu-
lar-weight heparin routinely used as thrombosis prophylaxis periop-Groin dissection and ligation is currently rarely performed
with laser ablation of the GSV in the United States. It is of little
value to translate the conclusions from this study to other reports
of EVL without GSV ligation. Some surgeons, who are able to
perform groin dissection, may still prefer to do so in conjunction
with laser ablation. It is never done when the laser procedure is
performed by nonsurgeons and in an office setting. This study does
not support to continue GSV ligation with EVL, because there was
no benefit to use the more expensive laser when it was combined
with groin ligation. The same result could be achieved by inserting
the inexpensive disposable stripper and removing the vein.
Groin neovascularization is probably triggered by the explo-
ration and ligation of saphenous tributaries and is frequently
associated with recurrence after surgery. This phenomenon is
largely avoided by the laser treatment with no groin dissection.
Long-term randomized studies to evaluate this aspect are still
lacking. Furthermore, it has been suggested that the risk of neo-
vascularization may be substantially decreased when tributaries
draining the abdominal wall are not ligated at the saphenofemoral
confluence. Again, this aspect needs to be tested in randomized
long-term studies.
